Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 22;13(21):6292.
doi: 10.3390/jcm13216292.

The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects

Piotr K Krajewski  1 , Aleksandra Złotowska  1 , Jacek C Szepietowski  2
Affiliations
Review

The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects

Piotr K Krajewski et al. J Clin Med. .

Abstract

Background: Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are synthetic peptides that mimic the natural activity of GLP-1, widely known for lowering blood glucose levels and promoting weight reduction. These characteristics make them a valuable tool in managing type 2 diabetes and obesity-related conditions. Recent findings indicate that GLP1-RAs may also offer therapeutic benefits in managing hidradenitis suppurativa (HS), a chronic inflammatory skin disorder closely associated with metabolic abnormalities, including obesity, diabetes, and dyslipidemia. This review explores the potential role of GLP1-RAs in managing HS. Methods: A systematic review was conducted by searching electronic databases, including MEDLINE and Google Scholar, without date limitations. Key search terms included "GLP-1" or "GLP-1 agonists" combined with "hidradenitis suppurativa" or "acne inversa". Inclusion criteria were set for studies reporting on the use of GLP1-RAs as a treatment for HS, with articles discussing theoretical applications excluded. Data synthesis included findings from 25 relevant studies. Results: The analysis revealed that GLP1-RAs, specifically liraglutide and semaglutide, led to significant reductions in weight and systemic inflammation in HS patients. Notably, improvements in lesion severity and quality of life were reported. The anti-inflammatory effects of GLP1-RAs were attributed to the suppression of key inflammatory pathways involving TNF-α, IL-17, and NF-κB. Conclusions: GLP1-RAs demonstrate significant potential as an adjunct therapy for HS, addressing both the metabolic and inflammatory aspects of the condition. While early results are promising, further research is necessary to determine their long-term efficacy in managing HS.

Keywords: GLP-1; GLP-1 agonists; acne inversa; hidradenitis suppurativa.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Literature search carried out according to the PRISMA guidelines.
Figure 2
Figure 2
Graphical presentation of HS pathogenesis.
Figure 3
Figure 3
Graphical presentation of the mechanism of action of GLP-1 receptor analogs.
Figure 4
Figure 4
Graphical presentation of possible effects of GLP-1 RAs in HS.
See this image and copyright information in PMC

References

    1. Meier J.J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2012;8:728–742. doi: 10.1038/nrendo.2012.140. - DOI - PubMed
    1. Nauck M.A., Quast D.R., Wefers J., Meier J.J. GLP-1 receptor agonists in the treatment of type 2 diabetes—State-of-the-art. Mol. Metab. 2021;46:101102. doi: 10.1016/j.molmet.2020.101102. - DOI - PMC - PubMed
    1. Jennings L., Nestor L., Molloy O., Hughes R., Moriarty B., Kirby B. The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide. Br. J. Dermatol. 2017;177:858–859. doi: 10.1111/bjd.15233. - DOI - PubMed
    1. González-López M.A. Hidradenitis suppurativa. Hidradenitis supurativa. Med. Clin. 2024;162:182–189. doi: 10.1016/j.medcli.2023.09.018. - DOI - PubMed
    1. Henry T., Cahn B., Haber R., Landers J.T., Berger-Fleishman R., Alam M., Hoyer S. Therapeutic potential of GLP-1 agonists for hidradenitis suppurativa. Int. J. Dermatol. 2023;62:1543–1544. doi: 10.1111/ijd.16892. - DOI - PubMed

LinkOut - more resources